Back to search

Japan· JP-2646709N1100

フルオシノロンアセトニド

A fluocinolone acetonide product containing フルオシノロンアセトニド, registered in Japan by 田辺ファーマ, on the national reimbursement list. The same ATC class is registered in 2 of our 19 countries.

On Japan’s NHI price listATC C05AA10

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedフルオシノロンアセトニドATCC05AA10REGISTER NO.JP-2646709N1100PACKS LISTED0CHECKEDSeptember 25, 2026

Where it is registered

Fluocinolone acetonide is registered in 2 of 19 countries.

Countries holding a registration under ATC C05AA10 (fluocinolone acetonide), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 1 of them publish a price we can compare per daily dose

Fluocinolone acetonide · ATC C05AA10

2 / 19 countries

  • Japan
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

MHLW / PMDA (Japan)
Active substance
フルオシノロンアセトニド
Manufacturer
田辺ファーマ
Country
Japan (JP)
ATC code
C05AA10
ATC class
Fluocinolone acetonide
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

10 interactions on record for fluocinolone acetonide.

Graded by severity as the source publishes them — 10 info. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Fluocinolone acetonide · interactions on record

10 records

Interaction register. Grades as the source publishes them.

Same medicine, other countries

Fluocinolone acetonide in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All fluocinolone acetonide products

Authorised across Europe · EMA

The same active substance is authorised in 24 EEA countries. Names it is sold under:

  • Austria · Iluvien
  • Belgium · Iluvien
  • Bulgaria · Абрикорт, Флуцинар
  • Czechia · Flucinar, Iluvien
  • Germany · Flucinar, Iluvien
  • Denmark · Iluvien, Otazem
  • Spain · Ekzem, Fluocid Forte
  • Finland · Iluvien, Otazem
  • France · Iluvien
  • United Kingdom (Northern Ireland) · Iluvien, Synalar
  • Greece · Synalar Simple
  • Hungary · Flucinar
  • Ireland · Iluvien
  • Italy · Ekzem, Fluovitef
  • Lithuania · Flucinar
  • Luxembourg · Iluvien
  • Latvia · Flucinar
  • Netherlands · Iluvien
  • Norway · Iluvien, Otazem
  • Poland · Flucinar, Iluvien
  • Portugal · Ekzem, Iluvien
  • Romania · Fluocinolon Acetonid Laropharm
  • Sweden · Iluvien, Otazem
  • Slovakia · Flucinar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8e55c91f-08f7-45c9-82bf-7ff6e4ae88a5
GET /v1/drugs/8e55c91f-08f7-45c9-82bf-7ff6e4ae88a5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "0.025%1g",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "2646709N1100",
  "category": "外用薬",
  "price_yen": 14,
  "generic_name": "フルオシノロンアセトニド",
  "product_name_jp": null,
  "therapeutic_class": "2646",
  "transitional_expiry": null
}

See everything about fluocinolone acetonide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.